Cost-utility and Physiological Effects of ACT and BATD in Patients With Chronic Pain and Depression

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

234 participants

Study Classification

INTERVENTIONAL

Study Start Date

2020-07-01

Study Completion Date

2022-12-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Objectives: (1) To analyze the effectiveness of adding a group-based form of Acceptance and Commitment Therapy (ACT) or a behavioural activation program for depression (TACD) to the treatment as usual (TAU) for patients diagnosed of chronic pain and comorbid mild-moderate major depression; (2) To examine the cost-utility of these psychological treatments from healthcare and societal perspectives; (3) To measure a set of biomarkers alongside the RCT in order to know the physiological underpinnings of these psychological therapies and to identify potential predictors of treatment response.

Methodology: 12-month multisite, randomised, controlled trial (RCT) Centres: Parc Sanitari Sant Joan de Déu (St. Boi de Llobregat) and Hospital del Mar (Barcelona).

Participants. 225 adult patients with chronic pain that meet the diagnostic criteria for mild-moderate major depression will be randomly assigned to one of the three study arms: TAU + ACT vs. TAU + TACD vs. TAU.

Primary outcome: Quality of life. Secondary outcomes: pain intensity, depression severity, anxiety symptoms, pain catastrophising, and pain acceptance. Costs to the healthcare system and to society and quality adjusted life years (QALYs). In addition, the empirically validated app Multicenter Pain Monitor® will be used to monitor participants alongside the treatments (ecological momentary assessment). Biomarkers: hair cortisol and cortisone, corticosteroid-binding globulin (CBG), ACTH and cortisol in plasma, and genotyping of 5 polymorphisms in the FKBP5 gene involved in the regulation of the hypothalamic-pituitary-adrenal axis activity, cytokines, Th1: IL-6, IL-8, TNF-α; cytokines Th2: IL-10 + hsCRP test, and vitamin D levels. Main statistical analyses: Intention-to-Treat analyses that will include all participants who undergo random allocation, using multiple imputation to replace missing values. Linear mixed-effects models will be performed using Restricted Maximum Likelihood to estimate the parameters. Calculation of between-groups effect sizes using Cohen's d and of the number-needed-to-treat. Economic evaluation: cost-utility ratios evaluated by applying bootstrapping techniques, acceptability curves, and sensitivity analyses.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Internet-based Acceptance Based Psychotherapy As an Adjunct to Chronic Pain Rehabilitation

NCT06816082

Chronic Pain

RECRUITING NA

Behavioural Activation and Severe Learning Disabilities

NCT06851741

Intellectual Disabilities Depression

NOT_YET_RECRUITING NA

Behavioral Activation for Major Depression With and Without Mindfulness

NCT04768361

Major Depressive Disorder

COMPLETED NA

Efficacy of Two Internet Delivered Intervention Programs for Depression: Behavioral Activation vs Physical Activity

NCT02369393

Major Depressive Disorder

COMPLETED NA

Targeted ACT Compared to Supportive Therapy for Depression RCT

NCT06900608

Acceptance and Commitment Therapy Supportive Therapy

COMPLETED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The IMPACT Project's main objective is to determine the effectiveness of adding to the standard care of patients with chronic pain and mild to moderate major depression a group programme based on ACT or a group programme based on BATD and analyse the cost-utility of these psychological treatments from a health and social perspective. Likewise, both in chronic pain and in other usually associated psychiatric diseases, there is a ubiquitous lack of knowledge about what specific psychological and physiological mechanisms are modified by these third generation psychotherapies and how they relate to the observed clinical results. The potential predictors of response to these treatments are also unknown. In chronic musculoskeletal pain where central sensitization plays an important role, alterations have been found in different markers associated with an increased experience of pain. Some of these alterations in markers (e.g. high levels of pro-inflammatory cytokines) would also appear to be shared with other psychiatric diseases (major depression), a fact that would suggest a possible common mechanism involved in the etiopathogenesis of these diseases. Third generation psychotherapies have proven effective for pain management and regulation of the immune response. The IMPACT Multicentre Project (Improving Pain and Depression with ACT and BATD) will significantly expand the limited knowledge available about how ACT and BATD therapies exert their effects on relevant clinical improvement variables and will try to identify response predictive factors to these treatments.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Randomized Controlled Trial

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

PARALLEL

Single-blind, parallel-group, randomized controlled trial

Primary Study Purpose

TREATMENT

Blinding Strategy

DOUBLE

Investigators Outcome Assessors

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

TAU + Acceptance and Commitment Therapy (ACT)

This therapy is based, as the name implies, on the acceptance (not avoidance) of negative experiences as a coping strategy, and on committing to life values or objectives. ACT has been used for various conditions, including chronic pain. Since avoidance is a strategy frequently used by patients suffering from pain, the application of this therapy seems very appropriate. In fact, it has been proven that patients who accept their pain more are those who score lower in pain intensity, have less negative emotions and enjoy a better quality of life.

Group Type EXPERIMENTAL

Acceptance and Commitment Therapy (ACT)

Intervention Type BEHAVIORAL

Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.

Treatment as Usual (TAU)

Intervention Type OTHER

Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.

TAU + Behavioral Activation Therapy for Depression (BATD)

Behavioural and structured treatment based on the application of learning principles. Its objective is to counteract depressive symptoms and, as a consequence, to ensure that patients regain a productive and emotionally satisfying life. Its basic methodology consists in activating subjects with depression through programming and conduct of behaviours that are likely to increase the positive reinforcement of their context.

Group Type EXPERIMENTAL

Behavioral Activation Therapy for Depression (BATD)

Intervention Type BEHAVIORAL

Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.

Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.

Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.

Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.

Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.

Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about.

Treatment as Usual (TAU)

Intervention Type OTHER

Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.

Treatment as Usual (TAU)

Standard Care. Although there is no treatment considered as the gold standard for chronic pain and comorbid major depression, the standard treatment is usually mainly pharmacological and conforms to the symptomatic profile of each patient.

Group Type ACTIVE_COMPARATOR

Treatment as Usual (TAU)

Intervention Type OTHER

Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Acceptance and Commitment Therapy (ACT)

Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Presentation of the general concept of ACT therapy. Session 2: Value analysis I. Session 3: Value analysis II. Session 4: Value analysis III. Session 5: Values and feelings. Session 6: Taking a direction. Session 7: Dare and change. Session 8: Ready to act with ACT.

Intervention Type BEHAVIORAL

Behavioral Activation Therapy for Depression (BATD)

Group treatment protocol of 8 weekly 90 minute sessions. Session 1: Collection of information regarding areas of activity and interaction contexts.

Session 2: Identification of information related to depressive behaviours. Session 3 Obtaining complementary information regarding the characteristics of the history of patient interactions and any contexts.

Session 4: Explanation of the hypotheses of problematic behaviour, its maintenance and change throughout the intervention.

Session 5: Once the 10 target activities have been identified, a record is made to track and their progress weekly.

Session 6: Discussion of what was obtained from the records in general and of the satisfaction obtained, and explanation of the contexts and reinforcers.

Session 7: Psycho-education Session 8: New behaviours, the goals achieved and the maintenance of the weekly activity are inquired about.

Intervention Type BEHAVIORAL

Treatment as Usual (TAU)

Standard pharmacological treatment usually provided to patients suffering chronic pain and mild-moderate depression.

Intervention Type OTHER

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

Patients who have been visited in the last 3 years in the participating centres and who have been given a diagnosis of chronic non-cancer musculoskeletal pain. In telephone screening, it will be evaluated whether the current pain intensity is at least moderate and PHQ-9 will be administered to confirm the presence of mild to moderate active depression.

1. Patients between 18 and 70 years of age.
2. Diagnosis of chronic pain (≥ 3 months) according to medical history (current pain ≥ 4 out of 10)
3. Diagnosis of mild to moderate depression according to PHQ-9 (score between 5 and 19).
4. Understanding of Spanish.
5. Access to a Smartphone (with Android operating system).
6. Written informed consent.

Exclusion Criteria

1. Presence of cognitive impairment according to MMSE (≤ 24 out of 30).
2. Previous (last year) or current psychological treatment.
3. Presence of severe mental disorder (e.g. psychotic disorder) related to substance dependence/abuse or another disease that affects the CNS (organic brain pathology or head trauma of any severity).
4. Presence of serious, uncontrolled or degenerative medical disease that may interfere with affective symptoms.
5. Risk of suicide (Item 9 score of PHQ-9 ≥ 2).
6. Patients involved in legal proceedings with employers in relation to their illness.
7. Patients with scheduled surgical intervention or other interventions.
8. Inability to attend group treatment sessions.

1. Cold/infection symptoms on the day of blood collection.
2. Needle phobia.
3. BMI \> 36 kg/m2 or weight \> 110 kg
4. Consumption \> 8 units of caffeine per day (maximum 1 drink with caffeine on the day of testing).
5. Smoker \> 5 cigarettes a day.
6. Being pregnant or breastfeeding

Minimum Eligible Age

18 Years

Maximum Eligible Age

70 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No